1. Home
  2. EVER vs GYRE Comparison

EVER vs GYRE Comparison

Compare EVER & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVER
  • GYRE
  • Stock Information
  • Founded
  • EVER 2008
  • GYRE 2002
  • Country
  • EVER United States
  • GYRE United States
  • Employees
  • EVER N/A
  • GYRE N/A
  • Industry
  • EVER Computer Software: Programming Data Processing
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVER Technology
  • GYRE Health Care
  • Exchange
  • EVER Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • EVER 929.6M
  • GYRE 897.1M
  • IPO Year
  • EVER 2018
  • GYRE N/A
  • Fundamental
  • Price
  • EVER $23.38
  • GYRE $8.18
  • Analyst Decision
  • EVER Strong Buy
  • GYRE
  • Analyst Count
  • EVER 5
  • GYRE 0
  • Target Price
  • EVER $32.40
  • GYRE N/A
  • AVG Volume (30 Days)
  • EVER 534.3K
  • GYRE 77.8K
  • Earning Date
  • EVER 08-04-2025
  • GYRE 08-11-2025
  • Dividend Yield
  • EVER N/A
  • GYRE N/A
  • EPS Growth
  • EVER N/A
  • GYRE N/A
  • EPS
  • EVER 1.24
  • GYRE 0.02
  • Revenue
  • EVER $615,246,000.00
  • GYRE $102,189,000.00
  • Revenue This Year
  • EVER $32.07
  • GYRE $21.04
  • Revenue Next Year
  • EVER $11.08
  • GYRE $89.64
  • P/E Ratio
  • EVER $18.83
  • GYRE $176.20
  • Revenue Growth
  • EVER 92.92
  • GYRE N/A
  • 52 Week Low
  • EVER $16.63
  • GYRE $6.11
  • 52 Week High
  • EVER $30.03
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • EVER 45.47
  • GYRE 58.07
  • Support Level
  • EVER $22.37
  • GYRE $7.35
  • Resistance Level
  • EVER $23.99
  • GYRE $8.30
  • Average True Range (ATR)
  • EVER 1.03
  • GYRE 0.45
  • MACD
  • EVER -0.11
  • GYRE 0.08
  • Stochastic Oscillator
  • EVER 34.88
  • GYRE 92.86

About EVER EverQuote Inc.

EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: